01 · Pre-trial
Design trials that can detect change
- Imaging protocol design
- Power calculations
- Site training and qualification
The future of MRI analysis
Next generation data analytics in neurology
QSA applies the latest imaging and machine learning technologies to show more precisely where treatments are working, across every stage of a clinical trial.
- 01
Pre-trial
Imaging protocol design and power calculations for enriched trials
- 02
During trial
Trial enrichment, patient staging and quality-managed imaging
- 03
Post-trial
Causal modelling, biomarker integration and brain age
1992UCL Queen Square MRI trials unit established
Nature CommunicationsSuStaIn MS subtypes, 2021
BrainTwo biological MS patterns, 2025
Royal SocietyEntrepreneur in Residence, 2021–22
Services
From protocol design to post-trial analysis
Core trial operations and advanced specialised analyses, delivered by the team behind UCL's MS imaging research.
02 · During trial
Run imaging with full auditability
- Image receipt and quality control
- Trial enrichment
- Quality management (ISO 9001:2015)
03 · Post-trial
Find where treatments work
- Data-driven patient staging
- Machine-learning prognosis
- Causal modelling and brain age
Science
SuStaIn: machine learning that stages and subtypes MS
The SuStaIn algorithm is a new generation of machine learning model that predicts a personalised prognosis for people with multiple sclerosis. It can shorten clinical trials, especially in progressive MS, and speed up drug development.
“By using an AI model combined with a highly available blood marker with MRI, we have been able to show two clear biological patterns of MS for the first time.”
About
Built on three decades of MS imaging at UCL
- 1992MS clinical trials office established at Queen Square (beta-interferon study)
- 2018Subtype and Stage Inference (SuStaIn) machine-learning method published in Nature Communications
- 2020Queen Square Analytics incorporated as a UCL spin-out
- 2021New MS subtypes identified with SuStaIn, published in Nature Communications
- 2023Partnership with Bioxydyn for neurological clinical trials
- 2025Two biological MS subtypes identified from MRI and a blood biomarker, published in Brain
News
Latest from QSA
Autolus pioneers CAR-T cell MS treatment
QSA is providing advanced imaging analytics for the BOBCAT trial of obe-cel, a one-time immunotherapy for progressive MS.
ARIAEducation.eu online resource launched
A joint QSA and UCL resource teaching clinicians and patients about amyloid-related imaging abnormalities.
AI analysis of blood tests and MRI reveals two types of MS
Research published in Brain, covered by the Guardian, the Independent and BBC Radio 4.
Careers
A fully remote team with roots at UCL
We look for people in advanced image analysis, ideally with MRI or neurology experience. We work remotely, meet regularly in London, and don't require relocation. Careers at QSA
Planning a neurology trial?
Tell us about your study and the imaging questions behind it.